Polycythemia Vera (PV) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Polycythemia Vera (PV)

Polycythemia Vera (PV) - Thelansis Epidemiology study reflects the prevalence of polycythemia vera varies worldwide. The condition affects an estimated 44 to 57 per 100,000 individuals in the United States. Men develop polycythemia vera more frequently than women.

Competitive landscape of PV includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of PV across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

PV Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing , Market Event and Product Event , Country specific Forecast Model , Market uptake and patient share uptake , Attribute Analysis , Analog Analysis , Disease burden and pricing scenario, Summary and Insights.

Read more: Polycythemia Vera (PV) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Asset                         Company                     

1        Drug: PTG-300                 Protagonist Therapeutics, Inc.

2        Drug: FEDRATINIB           Celgene       

3        Biological: P1101              PharmaEssentia Japan K.K. 

4        Drug: Imetelstat                Geron Corporation

5        Drug: NS-018                    NS Pharma, Inc.      

6        Drug: lestaurtinib               Cephalon       

7        Drug: Pacritinib                  CTI BioPharma       

8        Drug: IMG-7289                 Imago BioSciences,Inc.

9        Drug: panobinostat            Novartis

10        Drug: KRT-232                Kartos Therapeutics, Inc.

11        Drug: PU-H71                  Samus Therapeutics, Inc.

12        Drug: PXS-5505              Pharmaxis       

13        Biological: PRM-151       Hoffmann-La Roche

14        Drug: AZD1480               AstraZeneca               

15        Drug: Momelotinib          Sierra Oncology, Inc.

16        Drug: Simtuzumab         Gilead Sciences   

17        Drug: TG101348            TargeGen       

18        Drug: Dasatinib              Bristol-Myers Squibb

19        Drug: SB1518                S*BIO               

20        Drug: Selinexor             Karyopharm Therapeutics Inc

21        Drug: CPI-0610            Constellation Pharmaceuticals

22        Drug: parsaclisib           Incyte Corporation

23        Drug: LY2784544          Eli Lilly and Company

24        Drug: Plitidepsin            PharmaMar

25        Drug: SAR302503         Sanofi           

26        Drug: AVID200              Formation Biologics/Forbius, Inc.

27        Drug: ITF2357              Italfarmaco              

28        Drug: Ruxolitinib           Ascentage Pharma Group Inc.

29        Drug: rigosertib             Onconova Therapeutics, Inc.

30        Drug: Anagrelide CR     Galena Biopharma, Inc.

31        Drug: Fentanyl SS         INSYS Therapeutics Inc

32        Drug: Ruxolitinib            Actuate Therapeutics Inc.

33        Drug: forodesine hydrochloride    BioCryst Pharmaceuticals

34        Drug: IPI-926                 Infinity Pharmaceuticals, Inc.

35        Drug: Ruxolitinib            AbbVie            

36        Drug: TAS1553              Astex Pharmaceuticals, Inc.